Innovation

pharma& drives innovation through a fully integrated model unique for a company of our size and heritage, including active pharmaceutical ingredient (API) manufacturing, and secondary packaging and development. Our agile structure empowers us to meet our mission of preserving the availability and fostering the further development of essential medicines worldwide to leave no patient behind.

API Manufacturing & Secondary Packaging

pharma&’s wholly owned subsidiary, Loba biotech GmbH, ensures stable production of the active pharmaceutical ingredient (API), peginterferon alfa-2a. This secures the future availability of this treatment for eligible patients.

Our secondary packaging facility, pharma& Scheibbs, provides scalable solutions to support efficiencies across our portfolio.

Development

We foster the further development of essential medicines, including our current treatments, and invest in novel therapies, to leave no patient behind. These efforts reinforce our commitment to innovation and patient care.